As well as being home to countless blue chip shares, the Australian share market is home to a good number of promising small caps.
Three small cap shares that could be worth adding to your watchlist are listed below. Here's what you need to know about them:
Image source: Getty Images
Avita Medical Ltd (ASX: AVH)
The first small cap ASX share to look at is Avita Medical. It is a global regenerative medicine company best known for its Recell system. This is a spray-on skin treatment used for burns victims. It is also looking to use its system to treat vitiligo and is working on a project with Houston Methodist Research Institute on reversing cellular ageing. Bell Potter is positive on the company. It has a speculative buy rating and $9.80 price target on its shares.
Damstra Holdings Ltd (ASX: DTC)
Another small cap to watch is Damstra. It is a growing integrated workplace management solutions provider. Its cloud-based workplace management platform is used by businesses globally to track, manage, and protect their workers and assets. It recently reported that annual recurring revenue (ARR) reached $35 million at the end of June. This was up 65% over the prior corresponding period. Pleasingly, this is still only a small slice of its total addressable market (TAM). Management estimates that its TAM will be worth US$20 billion by 2022. In response to its update, Shaw and Partners retained its buy rating and $1.88 price target.
Mach7 Technologies Ltd (ASX: M7T)
A final small cap ASX share to watch is Mach7. It is a medical imaging data management solutions provider that allows users to create a clear and complete view of the patient. Users then use this to help them inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Demand for this type of software continues to grow thanks to industry tailwinds such as telehealth. The company estimates that its TAM is currently US$2.75 billion. This is materially more than the annual revenue of $19 million and $19.5 million it expects to report in FY 2021. Morgans is a fan of the company. It currently has an add rating and $1.56 price target on the company's shares.
